CNSP
CNS Pharmaceuticals, Inc.
Price Chart
Latest Quote
$4.70
+0.17 (+3.75%)
Current Price
| Previous Close | $4.53 |
| Open | $4.50 |
| Day High | $4.71 |
| Day Low | $4.45 |
| Volume | 13,493 |
Stock Information
| Shares Outstanding | 1.46M |
| Total Debt | $232K |
| Cash Equivalents | $2.95M |
| Net Income | $-16.49M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $6.87M |
| EPS (TTM) | $-24.12 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $4.05M |
| Income | $-16.49M |
| Book/sh | $0.09 |
| Cash/sh | $2.02 |
| Employees | 8 |
Financial Ratios
| Quick Ratio | 0.64 |
| Current Ratio | 0.89 |
| Debt/Eq | 328.62 |
Returns & Margins
| ROA | -112.92% |
| ROE | -298.64% |
Ownership
| Insider Ownership | 0.55% |
| Institutional Ownership | 12.03% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -12.05 |
| P/B | 54.02 |
Analyst Data
| Recommendation | none |
| Target Price | $10.00 |
Technical Indicators
| SMA20 | $4.95 |
| SMA50 | $4.39 |
| SMA200 | $5.60 |
| RSI | 34.58 |
| ATR | 0.3341 |
| Shares Float | 1.45M |
| Short Float | 3.34% |
| Short Ratio | 0.01 |
| Volatility | 1.03 |
| Rel Volume | 0.38 |
Performance History
| Week | -0.42% |
| Month | -1.67% |
| Quarter | +116.59% |
| 6 Months | -36.40% |
| YTD | -11.32% |
| Year | -52.75% |
| 3 Years | -99.99% |
| 5 Years | -100.00% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $4.70 | 26,700 |
| 2026-06-17 | $4.53 | 7,500 |
| 2026-06-16 | $4.63 | 17,700 |
| 2026-06-15 | $4.74 | 9,000 |
| 2026-06-12 | $4.89 | 21,100 |
| 2026-06-11 | $4.72 | 18,500 |
| 2026-06-10 | $4.61 | 30,800 |
| 2026-06-09 | $4.59 | 44,700 |
| 2026-06-08 | $4.89 | 20,100 |
| 2026-06-05 | $5.00 | 13,600 |
| 2026-06-04 | $5.28 | 21,200 |
| 2026-06-03 | $5.24 | 25,100 |
| 2026-06-02 | $4.92 | 10,200 |
| 2026-06-01 | $5.03 | 17,500 |
| 2026-05-29 | $5.44 | 24,700 |
| 2026-05-28 | $4.89 | 41,900 |
| 2026-05-27 | $5.12 | 75,400 |
| 2026-05-26 | $5.22 | 944,600 |
| 2026-05-22 | $5.42 | 23,700 |
| 2026-05-21 | $5.05 | 16,300 |
| 2026-05-20 | $5.10 | 48,000 |
| 2026-05-19 | $4.78 | 26,000 |
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.
đ° Latest News
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $15,230 | $16,120 | $13,805 | $7,027 |
| Total Expenses | $15,986,559 | $14,901,943 | $18,865,108 | $15,267,107 |
| Other Income Expense | $-2,560 | - | - | - |
| Other Non Operating Income Expenses | $-2,560 | - | - | - |
| Net Non Operating Interest Income Expense | $138,555 | $44,142 | $13,882 | $-7,027 |
| Interest Expense Non Operating | $15,230 | $16,120 | $13,805 | $7,027 |
| Operating Expense | $15,986,559 | $14,901,943 | $18,865,108 | $15,267,107 |
| General And Administrative Expense | $6,214,619 | $5,611,800 | $4,769,502 | $5,967,052 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-15,850,564 | $-14,857,801 | $-18,851,226 | $-15,274,134 |
| Net Interest Income | $138,555 | $44,142 | $13,882 | $-7,027 |
| Interest Income | $153,785 | $60,262 | $27,687 | $0 |
| Normalized Income | $-15,850,564 | $-14,857,801 | $-18,851,226 | $-15,274,134 |
| Net Income From Continuing And Discontinued Operation | $-15,850,564 | $-14,857,801 | $-18,851,226 | $-15,274,134 |
| Total Operating Income As Reported | $-15,986,559 | $-14,901,943 | $-18,865,108 | $-15,267,107 |
| Net Income Common Stockholders | $-15,850,564 | $-14,857,801 | $-18,851,226 | $-15,274,134 |
| Net Income | $-15,850,564 | $-14,857,801 | $-18,851,226 | $-15,274,134 |
| Net Income Including Noncontrolling Interests | $-15,850,564 | $-14,857,801 | $-18,851,226 | $-15,274,134 |
| Net Income Continuous Operations | $-15,850,564 | $-14,857,801 | $-18,851,226 | $-15,274,134 |
| Pretax Income | $-15,850,564 | $-14,857,801 | $-18,851,226 | $-15,274,134 |
| Interest Income Non Operating | $153,785 | $60,262 | $27,687 | $0 |
| Operating Income | $-15,986,559 | $-14,901,943 | $-18,865,108 | $-15,267,107 |
| Per Share | ||||
| Diluted EPS | $-35.75 | $-466.89 | $-91068.72 | $-288191.21 |
| Basic EPS | $-35.75 | $-466.89 | $-91068.72 | $-288191.21 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-15,831,416 | $-14,838,375 | $-18,833,287 | $-15,255,351 |
| Reconciled Depreciation | $3,918 | $3,306 | $4,134 | $11,756 |
| EBITDA (Bullshit earnings) | $-15,831,416 | $-14,838,375 | $-18,833,287 | $-15,255,351 |
| EBIT | $-15,835,334 | $-14,841,681 | $-18,837,421 | $-15,267,107 |
| Diluted Average Shares | $443,369 | $31,823 | $207 | $53 |
| Basic Average Shares | $443,369 | $31,823 | $207 | $53 |
| Diluted NI Availto Com Stockholders | $-15,850,564 | $-14,857,801 | $-18,851,226 | $-15,274,134 |
| Research And Development | $9,771,940 | $9,290,143 | $14,095,606 | $9,300,055 |
| Selling General And Administration | $6,214,619 | $5,611,800 | $4,769,502 | $5,967,052 |
| Other Gand A | $6,214,619 | $5,611,800 | $4,769,502 | $5,967,052 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $4,522,556 | $6,176,611 | $-4,432,115 | $8,132,856 |
| Total Assets | $8,623,466 | $8,700,943 | $1,700,853 | $13,053,115 |
| Total Non Current Assets | $520,665 | $42,435 | $109,683 | $488,470 |
| Non Current Prepaid Assets | $502,962 | $36,430 | $104,750 | $482,806 |
| Current Assets | $8,102,801 | $8,658,508 | $1,591,170 | $12,564,645 |
| Other Current Assets | $856,301 | $1,293,954 | $839,590 | $2,509,238 |
| Current Deferred Assets | $45,486 | $20,637 | $202,859 | $0 |
| Receivables | $0 | $882,539 | $0 | - |
| Accounts Receivable | $0 | $882,539 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $7,201,014 | $6,461,378 | $548,721 | $10,055,407 |
| Cash And Cash Equivalents | $7,201,014 | $6,461,378 | $548,721 | $10,055,407 |
| Cash Financial | - | - | $548,721 | $10,055,407 |
| Non Current Deferred Assets | - | - | - | $0 |
| Prepaid Assets | - | - | - | $2,509,238 |
| Debt | ||||
| Total Debt | $328,571 | $326,072 | $300,806 | $409,968 |
| Current Debt And Capital Lease Obligation | $328,571 | $326,072 | $300,806 | $409,968 |
| Current Debt | $328,571 | $326,072 | $300,806 | $409,968 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,100,910 | $2,524,332 | $6,132,968 | $4,920,259 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $4,100,910 | $2,524,332 | $6,132,968 | $4,920,259 |
| Current Notes Payable | $328,571 | $326,072 | $300,806 | $409,968 |
| Payables And Accrued Expenses | $3,772,339 | $2,198,260 | $5,832,162 | $4,510,291 |
| Payables | - | - | - | $3,681,900 |
| Accounts Payable | - | - | - | $3,681,900 |
| Equity | ||||
| Common Stock Equity | $4,522,556 | $6,176,611 | $-4,432,115 | $8,132,856 |
| Total Equity Gross Minority Interest | $4,522,556 | $6,176,611 | $-4,432,115 | $8,132,856 |
| Stockholders Equity | $4,522,556 | $6,176,611 | $-4,432,115 | $8,132,856 |
| Retained Earnings | $-100,275,268 | $-84,424,704 | $-69,566,903 | $-50,715,677 |
| Other | ||||
| Ordinary Shares Number | $632,516 | $117,796 | $207 | $53 |
| Share Issued | $632,516 | $117,796 | $207 | $53 |
| Tangible Book Value | $4,522,556 | $6,176,611 | $-4,432,115 | $8,132,856 |
| Invested Capital | $4,851,127 | $6,502,683 | $-4,131,309 | $8,542,824 |
| Working Capital | $4,001,891 | $6,134,176 | $-4,541,798 | $7,644,386 |
| Total Capitalization | $4,522,556 | $6,176,611 | $-4,432,115 | $8,132,856 |
| Additional Paid In Capital | $104,797,191 | $90,601,197 | $65,134,786 | $58,846,916 |
| Capital Stock | $633 | $118 | $2 | $1,617 |
| Common Stock | $633 | $118 | $2 | $1,617 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Net PPE | $17,703 | $6,005 | $4,933 | $5,664 |
| Current Accrued Expenses | - | - | - | $828,391 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-13,829,282 | $-17,117,487 | $-14,143,932 | $-10,562,237 |
| Operating Activities | ||||
| Operating Cash Flow | $-13,811,107 | $-17,113,299 | $-14,140,031 | $-10,557,815 |
| Cash Flow From Continuing Operating Activities | $-13,811,107 | $-17,113,299 | $-14,140,031 | $-10,557,815 |
| Operating Gains Losses | $2,559 | $-190 | $498 | $3,111 |
| Investing Activities | ||||
| Capital Expenditure | $-18,175 | $-4,188 | $-3,901 | $-4,422 |
| Investing Cash Flow | $-18,175 | $-4,188 | $-3,901 | $-4,422 |
| Cash Flow From Continuing Investing Activities | $-18,175 | $-4,188 | $-3,901 | $-4,422 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-2,043 | $0 | - | - |
| Issuance Of Capital Stock | $14,046,430 | $23,376,375 | $2,317,599 | $16,038,093 |
| Financing Cash Flow | $14,568,918 | $23,030,144 | $4,637,246 | $15,613,127 |
| Cash Flow From Continuing Financing Activities | $14,568,918 | $23,030,144 | $4,637,246 | $15,613,127 |
| Net Other Financing Charges | $818,457 | $-66,750 | $-202,859 | - |
| Net Common Stock Issuance | $14,044,387 | $23,376,375 | $2,317,599 | $16,038,093 |
| Common Stock Issuance | $14,046,430 | $23,376,375 | $2,317,599 | $16,038,093 |
| Other | ||||
| Repayment Of Debt | $-297,553 | $-300,806 | $-438,733 | $-427,700 |
| Interest Paid Supplemental Data | $15,267 | $13,599 | $13,805 | $8,094 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $7,201,014 | $6,461,378 | $548,721 | $10,055,407 |
| Beginning Cash Position | $6,461,378 | $548,721 | $10,055,407 | $5,004,517 |
| Changes In Cash | $739,636 | $5,912,657 | $-9,506,686 | $5,050,890 |
| Proceeds From Stock Option Exercised | $3,627 | $21,325 | $2,961,239 | $2,734 |
| Common Stock Payments | $-2,043 | $0 | - | - |
| Net Issuance Payments Of Debt | $-297,553 | $-300,806 | $-438,733 | $-427,700 |
| Net Short Term Debt Issuance | $-297,553 | $-300,806 | $-438,733 | $-427,700 |
| Short Term Debt Payments | $-297,553 | $-300,806 | $-438,733 | $-427,700 |
| Net PPE Purchase And Sale | $-18,175 | $-4,188 | $-3,901 | $-4,422 |
| Purchase Of PPE | $-18,175 | $-4,188 | $-3,901 | $-4,422 |
| Change In Working Capital | $1,845,252 | $-3,693,874 | $3,699,146 | $3,164,348 |
| Change In Payables And Accrued Expense | $1,542,453 | $-3,633,902 | $1,321,871 | $2,303,897 |
| Change In Prepaid Assets | $302,799 | $-59,972 | $2,377,275 | $860,451 |
| Stock Based Compensation | $187,728 | $838,957 | $1,007,417 | $1,202,966 |
| Depreciation Amortization Depletion | $3,918 | $3,306 | $4,134 | $11,756 |
| Depreciation And Amortization | $3,918 | $3,306 | $4,134 | $11,756 |
| Depreciation | $3,918 | $3,306 | $4,134 | $11,756 |
| Gain Loss On Sale Of PPE | $2,559 | $-190 | $498 | $3,111 |
| Net Income From Continuing Operations | $-15,850,564 | $-14,857,801 | $-18,851,226 | $-15,274,134 |
| Other Non Cash Items | - | $596,303 | - | - |
| Asset Impairment Charge | - | - | $0 | $334,138 |
| Change In Accrued Expense | - | - | - | $603,442 |
| Change In Payable | - | - | - | $1,700,455 |
| Change In Account Payable | - | - | - | $1,700,455 |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Payments | - | - | - | - |
Fetched: 2026-06-17